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Summary
Background: Small-cell lung cancer (SCLC), one of the major
types of lung cancer, is associated with many different somatic
molecular genetic changes. These alterations, observed in
tumor DNA, have also been identified in the plasma DNA of
patients. We undertook the present study to make a prospective
investigation into the correlation between abnormal plasma
DNA and patient survival.
Patients and methods: Thirty-five patients with SCLC were
selected after histological diagnosis. Polymorphic markers
(ACTBP2, UT762 and AR) were chosen for their reported
high rate of alterations in SCLC and analyzed in tumor tissue,
normal blood cells and plasma DNA. Furthermore, we looked
for mutations of the TP53 gene in tumor and plasma DNA.
Results: In 25 patients (71%) at least one molecular change
precisely matching that of the primary tumor was detected in
the plasma DNA. No difference in survival was observed
between patients with aberrant plasma DNA and patients
without plasma DNA alterations. However, patients with
microsatellite modifications and TP53 mutations concomi-
tantly, showed a significant difference (P = 0.02) in survival
compared with patients bearing only one of these molecular
changes. In 15 cases it was possible to find a correlation either
between tumor response and disappearance of abnormal
plasma DNA, or tumor progression and persistence of plasma
DNA alterations.
Conclusions: Free plasma DNA with molecular alterations
is present to a high degree in plasma DNA of SCLC patients
and may have a role as a prognostic factor.
Key words: circulating DNA, plasma DNA alterations, prog-
nostic factor, SCLC, tumor DNA alterations
Introduction
Small-cell lung cancer (SCLC) represents about 20% of
all primary lung cancers [1, 2]. The predominant risk
factor by far is cigarette smoking [3]. The tumor arises
from basal neuroendocrine cells, infiltrating the sub-
mucosa in the early stages of the disease [4]. Despite the
diversity and intensity of current therapies, survival is
usually short. In SCLC several clinical parameters have
been established as prognostic factors. Long-term sur-
vival has been associated to age, 65 years old or less at
diagnosis; performance status, ECOG 0-1; and limited
disease (LD) [5]. The overall survival rate of patients
treated with combination chemotherapy, with or with-
out chest irradiation, is about 7% at two years, ranging
from 2% for patients with extensive disease (ED) to 13%
with LD [5]. More recently, concurrent chemotherapy
and radiotherapy has been reported, in the case of LD,
to allow a 44% survival at two years [6].
SCLC is associated with different types of molecular
gene aberrations including somatic mutations of onco-
genes such as c-myc [7] or mutations of tumor suppressor
genes such as TP53 and RB [8, 9] as well as allelic loss
and microsatellite alterations in several chromosomal
regions [2, 10-14]. Detection of these molecular changes
may help define histological diagnosis or be used as a
prognostic factor.
Increased quantities of DNA have been found in the
plasma of patients suffering from different malignancies
[15-17]. This circulating extracellular DNA exhibits tumor
related alterations such as decreased strand stability [17],
ras orTP53 mutations [18-24], microsatellite alterations
[25-30] or aberrant promoter hypermethylation of tumor
suppressor genes [31-33].
Several studies seem to indicate that aberrations in
plasma/serum DNA may be used as a prognostic factor.
All patients suffering from head and neck cancer with
microsatellite alterations in the serum matching those of
the primary tumor had advanced disease [27]. Two
reports on pancreatic carcinoma provide evidence that
K-ras mutations in plasma DNA are linked to overall
survival [19, 34]. Nakamori and his group found that
patients showing ras mutations in plasma were more
likely to respond poorly to treatment, and those who
still harbored a mutation in the plasma, even after
seemingly successful surgery, had a poor prognosis
[34]. However, no prospective studies have been de-
signed to analyze the value of free plasma DNA during
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patient follow-up and its real implication as a predictive
factor.
In relation to lung cancer, quantitative studies show a
definite correlation between plasma DNA levels and
prognosis [35, 36]. Plasma DNA levels were increased in
patients with advanced disease and correlated with other
enzymatic tumor markers [35].
Moreover, microsatellite instability, expressed either
as a new allele or the loss of one allele [26], or aberrant
DNA methylation [31] have been shown to occur in
serum DNA of patients suffering from non-small-cell
lung cancer (NSCLC). In SCLC, 76% of the patients
presented a microsatellite alteration in the tumor DNA
and 71% in plasma DNA [25].
The purpose of this prospective phase II study was to
identify plasma DNA with similar features to tumor
DNA in SCLC patients, using microsatellite alterations
and TP53 mutations as molecular markers, and corre-
late them with patient survival, trying to investigate the
predictive value in the outcome of aberrant plasma
DNA.
Patients and methods
centrifuged at 14000 rpm for 30 min, after which the clear supernatant
was collected (25). Proteinase K (20 mg/ml) (Boehringer Mannheim,
Mannheim, Germany) and buffer AL (Qiagen Inc.) were added in a
1:10 proportion with respect to the collected supernatant, and incu-
bated overnight at 55 °C.
Clinical characteristics of the patients
Clinical staging procedures included chest X-rays, blood cell counts
and biochemical profiles, computed tomography of chest and abdo-
men, and finally bone scintigraphy. Computed tomography of the
brain was performed only when there was clinical suspicion of central
nervous system involvement. This study was designed as a prospective
phase II study with all patients undergoing the same treatment.
Patients with ED received four chemotherapy (CT) cycles based on
carboplatin 300 mg/m2 intravenously on day 1 plus etoposide 100
mg/m2, intravenously on day 1 and orally on days 2,3,4 and 5. Patients
with LD were submitted to the same treatment followed by chest
irradiation and two additional series of the same CT. Following treat-
ment, which usually lasted 28 weeks, clinical follow-up took place
every 12 weeks. Plasma was collected and the DNA analyzed on each
occasion. A median of 4 plasma samples (range 1-10) were examined
for each patient. Disease recurrence was treated with CT (cyclophos-
phamide, 1000 mg/m2 i.v. on day 1; adnamycin, 45 mg/m2 i.v. on day 1;
and vincristine 2 mg/m2 iv on day 1) until a second complete response
or disease progression was observed.
Patient population
Between May 1997 and January 1999, 35 patients with histologically
confirmed diagnosis of SCLC were recruited for this phase II study.
Informed consent was obtained from all participants after explaining
the nature of the study, which was approved by the Research Ethics
Board of our hospital. The median age of the patients was 61 years
(range 38-79 years). Thirty-one were male and four female. The disease
was classified as limited disease (LD) when tumor was restricted to
one hemithorax, including ipsilateral supraclavicular fossa, and any
wider disease including distant metastasis was classified as extensive
disease (ED). The 113-week follow-up period lasted from May 1997
until June 1999; the median follow-up time for all patients was 57
weeks. Patient survival was calculated as the interval between the date
of diagnosis and date of death or date of the last follow-up visit, and
was the major clinical endpoint.
Tissue samples
A blood sample was collected from each patient with histological
diagnosis of SCLC on the day prior to the first chemotherapy course.
The diagnosis of SCLC was based on histological analysis of tumor
samples collected at bronchoscopy or on cytological examination of
sputum. None of the patients underwent surgical extirpation of the
primary tumor or metastasis. Sixteen bronchial biopsy specimens
were available for molecular study. These were snap-frozen in liquid
nitrogen until processed. In addition. 13 healthy controls with no
history of cancer or other known disease were recruited from blood
donor volunteers.
DNA extraction
Blood cell and plasma DNA was extracted immediately. Tumor tissue
and blood cell DNA was purified by a nonorganic method (S-4520 Kit.
Oncor Inc., Gaithersburg. Maryland). Plasma DNA was extracted
using Qiagen columns (Qiamp Blood Kit, Qiagen Inc., Hilden, Ger-
many) according to the protocol for blood and body fluids with the
following modifications. Up to 12 ml of plasma previously heated on a
heat block to 99 °C for 5 min were used. The heated sample was then
Microsatellite analysis and PCR conditions
Three microsatellite markers were used to determine loss of
heterpzygosity (LOH) or microsatellite shift on chromosomes 5
(ACTBP2), 12 (UT762) and X(AR). These markers were previously
reported to show a high rate of microsatellite alterations in SCLC
patients [10]. PCR was performed in 25 ul volumes using 0.75 units of
Amph Taq Gold DNApolymerase (Perkin-Elmer, Roche Molecular
Systems, Inc, Branchburg, New Jersey), 2.5 ul of 10X PCR buffer, 200
uM dNTP, each primer at 0.6 uM with different concentrations of
MgCl2 depending on the polymorphic marker. A 35-cycle amplifica-
tion was performed in a thermal cycler (Perkin-Elmer, Cetus, Foster
City, California). The annealing temperatures were 59 °C, 62 °C and
57 °C, respectively. The alleles were separated by mixing 25 ul of PCR
products with a 10 ul volume of loading buffer (total volume 35 ul),
0.02% xylene cyanol and 0.02% bromophenol blue. Electrophoresis
was run on nondenaturing 8%-12% polyacrylamide gels for 12-15 h at
500 v. After gel electrophoresis, the allelic band intensity was detected
by a nonradioisotopic technique using a commercially available
silver staining method [37]. We analyzed the allelic intensities by
densitometry. The gel image was captured by a GS-690 Imaging
Densitometer (Bio-Rad laboratories, Hercules, California) digitized in
400 dpi, and analyzed by using Multi-Analyst/PC (Bio-Rad Labora-
tories, Hercules, California).
Ten of the results obtained were checked by laser fluorescence. One
primer of each set was labeled with a fluorescent dye at the 5' end and
all primers were purified by HPLC. Ten ng and 20 ng of plasma DNA,
20 ng of blood cell and tumor DNA were used as a template in a hot-
start PCR in a 25 ul reaction mixture: 1.5 mM MgCl2, 20 uM dNTP,
0.6 u Taq polymerase, 2-10 pmol of each primer (depending on the
primer). Each PCR reaction was carried out in the same conditions as
described above. PCR products were separated electrophoretically on
8% polyacrylamide gels and detected by laser fluorescence using an
automated gene sequencer (Alfexpress, Amersham-Pharmacia). Fluo-
rescent gel data was analyzed with the Allele-link 2 program. PCR
products from lymphocytes, corresponding blood plasma and tumor
tissue were analyzed on the same gel. The size in base pairs of the
microsatellite alleles was automatically calculated using internal size
markers. Automatic analysis of peak areas allowed relative quantifica-
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tion of PCR products and determination of allelic ratios. LOH was
scored if the allelic ratios of tumor or plasma PCR products and
corresponding lymphocyte PCR products were below a cut-off value
of 70%. Results indicating LOH were repeated at least twice.
Point mutations of thepS3 gene
Since up to 50% of SCLC patients were reported to exhibit TP53
mutations we also looked for the presence of point mutations in exons
5, 6, 7, and 8 of TP53 in the plasma DNA of SCLC patients. PCR-
SSCP analysis was performed according to a modification of the
method reported by Orita et al. [38]. The primers used for amplifica-
tion of the different exons were: 5-TCCTTCCTCTTCCTACAG and
5-ACCCTGGGCAACCAGCCCTGT for exon 5; 5-ACAGGGCTG-
GTTGCCCAGGGT, and 5-AGTTGCAAACCAGACCTCAGGCG for
exon 6; 5-TCCTAGGTTGGCTCTGACTGT and 5-AGTGGCCCT-
GACCTGGAGTCT for exon 7; and 5-GGGACAGGTAGGACC-
TGATTTCCTT and 5-ATCTGAAGGCATAACTGCACCCTTGG for
exon 8 (Source: J. Weissenbach, Genethon,Whitehead Institute Center
for Genome Research). The annealing temperatures were 65 °C, 67 °C,
62 °C and 68 °C, respectively. PCR was performed under standard
conditions in 25 ul that contained 2 ul (100 ng) of DNA template
(tumor, normal or plasma DNA); 2.5 ul of 10 X PCR buffer and 0.75 U
of Ampli Taq Gold (Perkin-Elmer, Roche Molecular Systems Inc.,
Branchburg, New Jersey); 200 uM dideoxynucleoside triphosphate
(dNTP) mix, each primer at 0.6 uM, different concentrations of
magnesium chloride depending on the primer, and distilled H2O
needed to reach the total volume. For PCR amplification, the samples
underwent 40 cycles at 94 °C for 1 minute, and were then subjected to
different annealing temperatures depending on the primer, and 70 °C
for 1 minute. The amplified products were denatured by mixing with
15 ul of denaturing stop solution that contained 98% formamide, 10
mmol/1 edathamil (pH 8.0), 0.02% xylene cyanol and 0.02% bromo-
phenol blue, heated to 95 °C for 5 minutes and rapidly cooled on ice.
Electrophoresis was run on nondenaturing 8%-12% polyacrylamide
gels for 12-15 hours at 250 v. The allelic band intensity on the gels was
detected by a nonradioisotopic method using a commercially available
silver staining method [37]. The specimens that showed a differential
band at SSCP were amplified to obtain templates for DNA sequencing.
These amplifications were independent from those used for SSCP
analysis. Amplified DNA fragments were purified from 0.9% agarose
gels using a Geneclean Kit (Bio-101, Inc., La Jolla, California), and used
for direct DNA sequencing with the dNTP method with a Sequenase
Kit (United States Biochemical Corp. Cleveland, Ohio).
Statistical analysis
Given the sample size of the study, it was considered that the statistical
power of the study was higher than 75%. The statistical study was
performed using SPSS version 7.5 for Windows (SPSS, Inc., Chicago,
Illinois) and included Kaplan-Meier for estimation of survival curves.
Differences between two curves were examined by the log-rank and
Breslow tests. The level of significance was set at < 0.05.
Results
Molecular alterations detected
We detected at least one molecular alteration, LOH or
shift, with microsatellite markers UT762, ACTBP2 and
AR (X) (Figures 1-3), or a mutation on TP53 gene
(Figure 4) in the plasma DNA of 25 of 35 patients
(71%). Twenty-two showed molecular alteration at the
time of diagnosis, for the remaining three it appeared
later during follow-up. In eight cases (23%), microsatel-
L T P1 P2 P3 P4
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Figure I. Photograph of the gels taken under normal light after
staining with a (NO3)Ag method showing microsatellite alterations at
the AR(X) marker in lymphocyte (L), tumor (T) and plasma (P) DNA
of patient # 2 2 . The sequence of plasma determinations (Pl-4) demon-
strates the persistence of microsatellite shift at the AR(X) marker at
the time of diagnosis (PI), after 4 courses of chemotherapy (P2) and
after combined treatment chemotherapy plus radiotherapy (P3), and
the disappearance of the microsatellite shift at 52 weeks (P4) coinci-
dent with complete disease remission. No alterations were detected at
markers ACTBP and UT762 throughout follow-up.
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Figure 2. Representative photograph of the gels taken under normal
light after staining with a (NO3)Ag method, showing microsatellite
alterations at the UT762 marker in lymphocyte (L), tumor (T) and
plasma (P) DNA of patient # 11. A loss of heterozygosity was observed
at marker UT762 throughout follow-up of the patient, from diagnosis
(PI) until death, 28 weeks later (P3) with no response to treatment.
There were no changes at markers AR(X) (homozygous in male
patients) or ACTBP.
lite alterations coincided with a TP53 mutation. Twelve
patients (34%) exhibited only microsatellite alterations,
and TP53 mutations alone were detected in five (14%).
Out of 16 available tumor samples, 12 (75%) presented
microsatellite alterations and/or TP53 mutations, 10 of
which (83%) showed similar molecular changes in the
plasma (Table 1). Analysis of microsatellite patterns by
laser fluorescence using an automated gene sequencer
(Figure 3) confirmed the results obtained with the silver
stained gels.
No difference in DNA pattern was detected between
plasma DNA samples and normal blood cell DNA from
13 healthy controls.
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Table 1. Clinical features and microsatellite alterations and TP53 gene mutations in plasma and tumor DNA in SCLC patients.
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Age/sex
70/M
72/M
45/M
60/F
52/M
59/M
79/M
60/M
70/M
60/M
38/F
42/M
63/M
60/M
42/F
68/M
67/M
61/M
65/M
69/M
70/M
69/F
67/M
50/M
50/M
75/M
76/M
55/M
64/M
57/M
68/M
48/M
65/M
50/M
56/M
Stage
ED
LD
LD
LD
LD
LD
LD
LD
LD
ED
LD
LD
ED
ED
LD
LD
ED
LD
LD
LD
LD
LD
LD
ED
LD
ED
ED
ED
LD
LD
LD
LD
LD
ED
ED
UT762
Turn
-
ND
ND
-
S
ND
LOH
ND
LOH
ND
LOH
-
-
ND
ND
-
S
-
ND
ND
ND
-
ND
ND
-
-
ND
ND
ND
-
ND
ND
-
ND
ND
PI
-
-
-
-
S
-
LOH
-
LOH
LOH
LOH
-
-
S
LOH
-
S
s
-
-
-
-
-
-
-
-
LOH
-
-
-
-
S
LOH
-
-
ACTBP2
Turn
-
ND
ND
-
-
ND
-
ND
-
ND
-
-
LOH
ND
ND
-
S
LOH
ND
ND
ND
-
ND
ND
-
-
ND
ND
ND
LOH
ND
ND
-
ND
ND
PI
-
-
-
-
-
-
-
S
-
-
-
-
LOH
-
-
-
-
LOH
-
LOH
LOH
-
-
-
-
-
-
-
-
-
-
-
-
S
-
AR(X)
Turn
-
ND
ND
-
S
ND
-
ND
-
ND
-
-
-
ND
ND
-
-
-
ND
ND
ND
S
ND
ND
-
S
ND
ND
ND
-
ND
ND
-
ND
ND
PI
-
-
-
-
S
-
-
-
-
-
-
s
-
-
-
-
-
-
-
s
-
s
-
-
-
s
-
-
-
-
-
s
-
-
-
TP53
Turn PI
-
ND +
ND -
-
+ +
ND -
+ +
ND -
-
ND -
-
-
-
ND -
ND +
-
-
+ +
ND +
-
ND -
+ +
ND -
ND -
+ +
+ +
ND +
ND -
ND +
-
ND -
ND -
+
ND +
ND +
Alteration,
Dg. time
N
N
N
N
Y
N
N
Y
N
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
N
Y
N
N
Y
Y
Y
Y
Alteration,
follow-up
N
Y
N
N
Y
N
Y
Y
Y
N
Y
N
Y
Y
Y
N
Y
Y
N
N
Y
Y
N
N
N
Y
Y
N
Y
N
N
N
N
Y
N
Abbreviations: F - female; M - male; ND - not done; N - absence of molecular alterations at diagnosis time or during the follow-up;
Y - Presence of molecular alterations at diagnosis time or during the follow-up; - - absence of S, LOH orTP53 mutations; + - presence of TP53
mutations; Turn - tumor DNA; PI - plasma DNA.
Survival data
According to stage at diagnosis, 24 patients had LD and
11 patients ED, with an equivalent proportion of LD or
ED patients having abnormal plasma DNA in both
subgroups. The overall median survival at the end of the
follow-up period was 42 weeks (range 4-97 weeks). Nine
patients remained alive, with a median follow-up of
thirty-three weeks (range 24-73 weeks), all of them
displayed molecular alterations in their plasma DNA,
and twenty-six patients died after a median survival time
of forty-three weeks (range 4-97 weeks). The 10 patients
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Figure 3. Original tracings from microsatellite analysis from plasma,
blood cell and tumor DNA of patient 9, with marker UT762. Plasma
and tumor DNA reveal LOH.
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Figure 4. Sequencing analysis in plasma DNA (B) of patient #29
shows a nucleotide change at codon 273 (C to G) in the direct
sequencing in exon 8 of the TP53 gene. This nucleotide change causes
an amino acid change (Arg-Gly). Panel (A) control sequence.
that showed no aberrant plasma DNA were dead at the
end of the study. All deaths were tumor related and non-
toxic deaths were registered.
Statistical analysis of survival in the different sub-
groups revealed the following results: (a), the compar-
ison between patients with aberrant plasma DNA at the
time of diagnosis (n = 22; median survival 57 weeks)
versus those patients with no DNA alterations (n = 10;
median survival 46 weeks), showed no statistically sig-
Survival time in weeks
Figure 5. Kaplan-Meier survival curves for patients with only micro-
satellites changes, or TP53 gene mutations, versus patients with both
type of alterations concomitantly, in free plasma DNA.
nificant difference (P - 0.4); (b), patients in whom
abnormal plasma DNA disappeared following treat-
ment (n = 11; median survival 33 weeks) and patients
with persistence of plasma DNA changes (n = 10;
median survival 57 weeks) did not differ significantly
(P = 0.5); (c), the survival of patients with only micro-
satellite alterations (n = 12; median survival 28 weeks)
or TP53 gene mutations (n = 5; median survival 59
weeks), did exhibit a statistically significant difference
{P = 0.02) regarding patients presenting both types of
DNA changes concomitantly (n = 8; median survival 70
weeks) (Figure 5).
Correlation between clinical development and molecular
events
In 15 patients (60%) of the 25 with abnormal plasma
DNA, a correlation was observed between the clinical
outcome and the presence of plasma DNA changes
(Table 2). Among these cases, three different subgroups
were distinguished: the first included four patients
(patients 5, 15, 29, 34) with partial or complete response
of their tumor to treatment and concomitantly the
disappearance of the plasma DNA molecular changes,
subsequently, with the persistence of partial response or
disease recurrence, new appearance of abnormal plasma
DNA was observed. The second group consisted of eight
patients (patients 8, 11, 13, 14, 17, 21, 26, 27) with no
response to treatment and no clearance of the plasma
DNA molecular changes. The third group, involved
three patients (patients 2, 7, 9) with no molecular alter-
ations at diagnosis and late appearance of plasma DNA
changes coincident with disease recurrence. In one of
these cases, the presence of de novo TP53 gene mutation
was detected 12 weeks prior to clinical relapse.
Discussion
Our study confirms the presence of microsatellite alter-
ations similar to those found in tumors in the plasma
DNA of SCLC patients [25]. However, it is the first
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Table 2. Clinical and molecular profiles of the 15 patients that showed a correlation between plasma DNA alterations and clinical outcome.
Patient Age/ Stage Alter. Survival time in weeks
sex at
diag. 16 28 40 52 64 76 100 112
2
5
7
8
9
11
13
14
15
17
21
26
27
29
34
72/M
51/M
79/M
60/M
70/M
38/F
63/M
60/M
42/F
67/M
70/M
73/M
76/M
64/M
50/M
LD
LD • •
LD
LD •
LD
LD •
ED •
ED •
LD •
ED •
LD •
ED • •
ED • •
LD •
ED •
CR/-
CR/-
CR/-
N R / B
CR/-
N R / B
N R / B
N R / i
PR/-
N R / B
N R / B
N R / B
N R / B »
CR/-
PR/-
CR/-
CR/-
DOD
NR/B
NR/B
DOD
PR/B
DOD
NR/B
NR/i«
D R / n
D R / B
N R / B
CR/*
PR/B*
CR/*
D R / B
DOD
DOD
DOD
D R / B *
DOD
NR/B*
DOD
DR/*
D R / B *
D R / B
DOD
DOD
DOD
AWD
AWD
DR/*
DOD
DOD
Abbreviations: AWD - alive with disease; DOD - died of the disease; ED - extensive disease; LD - limited disease; a - microsatellite
alterations; NED - no evidence of disease; NR - no response; CR - complete response; PR - partial response; DR - disease recurrence;
M - male; F - female; * - TP53 mutations.
report of SCLC patients where TP53 mutations were
detected in the same patients studied for microsatellite
alterations. The presence or absence of plasma DNA
with either microsatellite alterations alone, or the pres-
ence or absence of TP53 alone, had no influence on
patient survival. Only when microsatellite alterations
and TP53 were present together was the median survival
statistically higher than for patients with no plasma
DNA changes.
Although based on relatively small numbers, this
apparently paradoxical finding could be analogous to
the phenomenon observed on hereditary non-polyposis
colorectal cancer, where it was shown that patients with
replication errors (RER) had a better prognosis and
survival rate than those without RER [39]. A similar
correlation between better prognosis and RER positive
cancers has also been found in sporadic colorectal carci-
noma [40, 41], gastric [42, 43], endometrial carcinoma
[44], or cancer in the papilla of Vater [45]. Microsatellite
alterations and similarly TP53 mutations, especially in
exon 7 or 8, have been found to be associated with poor
prognosis in NSCLC [46-49] but to our knowledge
no report has been published on joint studies of p53
mutations and microsatellite instability or LOH on other
chromosomes. It does not seem illogical to assume that
cells with several genetic defects may be weaker and
more easily destroyed by, or be more accessible to,
chemotherapy [50]. In conclusion, the role of this asso-
ciation, which demonstrated a statistically significant
difference, as a factor for prognosis remains to be
established.
Regarding the correlation between the clinical out-
come of patients and the variations of aberrant plasma
DNA, in 60% of patients the type of response to treat-
ment was in parallel with persistence or disappearance
of abnormal plasma DNA, and moreover, in one patient
the reappearance of plasma DNA alterations preceded
the recurrence of the disease by 12 weeks. The predictive
value of a molecular marker as a possible early recur-
rence indicator that might be of some use in monitoring
the response to treatment, also of use in post-treatment
follow-up and complete response, is an important aspect
to consider.
Our study in small-cell lung cancer shows that aber-
rations in plasma DNA could sometimes be used as a
prognostic factor, an event which has been observed in
other malignancies [19, 34], however, larger studies
should be made to assess the real value of this fact.
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